Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Moderna revenue soars in Q4 thanks to COVID-19 vaccine

By Brian Buntz | February 26, 2021

Moderna

Moderna Logo (PRNewsFoto/Moderna Therapeutics)

Moderna posted mixed fourth-quarter results today with a larger-than-expected loss but beat the consensus forecast for revenue. The company boosted its outlook for the rest of the year, citing strong demand and maturing commercialization capabilities.

The Cambridge, Mass.-based vaccine developer reported revenue of $570.7 million for the three months ended Dec. 31, 2020. That figure was well ahead of the consensus estimate of $326.58 million. Revenue in the same period of 2019 was $14 million.

The company reported a loss of $272.5 million in its fourth quarter. That equated to a loss per share of –$0.69. Analysts had expected a loss of –$0.25. The company had a loss of $0.34 per share a year ago.

“2020 was a historic year for Moderna,” said the company’s CEO, Stéphane Bancel, in an earnings call. Beginning the year as “an early-stage development company,” the company had become a late-stage drug developer by the end of July. “And by December, we had positive results from our Phase III COVE study of our COVID-19 vaccine showing efficacy around 94%,” Bancel added.

Although best-known as a COVID-19 vaccine developer, the company has a pipeline of therapies for cancer, cardiovascular disease, and autoimmune disease. “We are not a COVID-19 vaccine company,” Bancel stressed.

Moderna anticipates $18.4 billion in sales in 2021. Analysts had estimated $11 billion.

Investors responded by sending MRNA shares up 2.5% to $148.48.


Filed Under: Uncategorized
Tagged With: coronavirus, covid-19, COVID-19 vaccine, Moderna, Stéphane Bancel
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

lab microscope
Accelerating R&D with FAIR data
Amylyx
Amylyx notches first global approval for oral ALS therapy Albrioza
Novavax
FDA advisory panel backs Novavax COVID-19
Sage and Biogen
Zuranolone could offer rapid relief from postpartum depression 

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50